Xolair (omalizumab) prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for omalizumab (Xolair) for severe asthma, nasal polyps, and chronic spontaneous urticaria for CareOregon members; defines initial and reauthorization requirements and approval lengths.
No material clinical or coverage changes in this revision.
Coverage Criteria for Omalizumab (Xolair)
Initial Therapy - Severe Asthma
Covered when ALL of the following are met for severe asthma (Initial Authorization):
[[chunk 4]]
[[chunk 4]]
[[chunk 4]]
[[chunk 4]]
[[chunk 4]]
[[chunk 4]]
[[chunk 4]]
[[chunk 4]]
[[chunk 5]]
[[chunk 5]]
Reauthorization - Severe Asthma
Reauthorization criteria for asthma:
[[chunk 6]]
Initial Therapy - Nasal Polyps
Covered when ALL of the following are met for nasal polyps (Initial Authorization):
[[chunk 6]]
[[chunk 7]]
[[chunk 7]]
[[chunk 7]]
[[chunk 7]]
[[chunk 7]]
Reauthorization - Nasal Polyps
Reauthorization criteria for nasal polyps:
[[chunk 7]]
Initial Therapy - Chronic Spontaneous Urticaria
Covered when ALL of the following are met for chronic spontaneous urticaria (Initial Authorization):
[[chunk 8]]
[[chunk 9]]
[[chunk 9]]
[[chunk 9]]
Reauthorization - Chronic Spontaneous Urticaria
Reauthorization criteria for chronic spontaneous urticaria:
[[chunk 10]]
[[chunk 11]]
The asthma pathway excludes members with evidence of perennial aeroallergen sensitization. Specifically, a positive skin test or RAST to a perennial aeroallergen disqualifies eligibility under the severe asthma initial authorization criteria.
Current tobacco use is not permitted for approval under the asthma criteria. The member must be not a current smoker to meet the eligibility requirements for Xolair in the severe asthma pathway.
Key Clinical Thresholds and Coding
Provider Requirements and Documentation
Obtain prior authorization — indication-specific criteria apply
Prior authorization is required for Xolair. Initial and reauthorization requirements differ by diagnosis (severe asthma, nasal polyps, chronic spontaneous urticaria) and include prescriber specialty, age/IgE ranges for asthma, required prior therapy failures, and documentation of benefit for reauthorization.
- Prescriber specialty requirements vary by indication (pulmonologist/immunologist for asthma; allergist or ENT for nasal polyps; allergist/immunologist for chronic spontaneous urticaria).
- Asthma initial criteria include age ≥6 and age-specific baseline IgE ranges.
- Reauthorization requires documentation of clinical benefit while on Xolair.
Document failure of required prior therapies
Members must have tried and failed specified prior therapies before approval. For asthma this includes high‑dose inhaled corticosteroid plus a long‑acting beta agonist, a long‑acting muscarinic antagonist, and a leukotriene inhibitor. For nasal polyps, failure of at least two intranasal corticosteroids and Sinuva is required. For chronic spontaneous urticaria, failure of at least two second‑generation antihistamines, dose escalation of an antihistamine, montelukast, and either hydroxyzine or an H2 antagonist is required.
- Asthma prior agents: high‑dose ICS+LABA (e.g., AirDuo, Advair, Symbicort), LAMA (e.g., Spiriva), leukotriene inhibitor (e.g., montelukast).
- Nasal polyps: ≥2 intranasal corticosteroids and Sinuva.
- Urticaria: ≥2 second‑generation antihistamines, higher‑than‑normal antihistamine dose, montelukast, and hydroxyzine or an H2 antagonist.
Provide supporting medical records with the request
Submit medical records (e.g., chart notes) to confirm the diagnosis and, when applicable for nasal polyps, to show that sinus surgery has been determined to not be medically appropriate.
- For nasal polyps include records demonstrating recurrent polyps after multiple sinus surgeries and documentation that surgery is not appropriate.
- For chronic spontaneous urticaria include chart notes confirming hives/angioedema duration ≥6 weeks.
Include reauthorization evidence of clinical benefit and provider attestation
For reauthorization, include documentation showing clinical improvement while on Xolair — e.g., reduction in asthma exacerbations requiring urgent care/ED visits, hospitalizations, or oral steroids; or a decrease in wheals/angioedema with improved sleep and daily functioning — and a provider statement that continued treatment is medically necessary and not appropriate to taper or stop.
- Asthma reauthorization: evidence of reduced exacerbations and sustained clinical improvement from baseline while on Xolair.
- Urticaria reauthorization: documented decrease in wheals/angioedema and improved ability to sleep/participate in activities, plus provider attestation of medical necessity.
Risk of denial for smoking, positive allergen testing, or out‑of‑range IgE/age
Denial risk if member is a current smoker, has a positive skin test or RAST to a perennial aeroallergen, or does not meet age or baseline IgE ranges required for the asthma indication.
- Asthma criteria require member is not a current smoker and has no positive skin test or RAST to a perennial aeroallergen.
- Baseline IgE ranges: age ≥12 years 30–700 IU/mL; ages 6–11 years 30–1,300 IU/mL.
Risk of denial if prior therapy trials are not documented
Denial risk if required prior therapies were not tried or documented. Examples: missing trials of high‑dose ICS+LABA, LAMA, and leukotriene inhibitor for asthma; missing trials of intranasal corticosteroids and Sinuva for nasal polyps; or missing required antihistamine and adjunctive therapy trials for urticaria.
- Ensure documentation of specific prior agent trials and failures (list of agents required differs by indication).
- For nasal polyps include prior surgery history and records if applicable; for urticaria include duration and prior therapy details.
Background: indications and selection criteria for Xolair
Omalizumab (Xolair) is indicated for moderate to severe allergic asthma with elevated IgE, recurrent nasal polyps, and chronic spontaneous urticaria refractory to standard therapies; policy frames patient selection by age, IgE thresholds, prior therapy failures, prescriber specialty, and required documentation of benefit.
- Approval lengths: initial nasal polyps and urticaria 6 months; asthma reauthorization and urticaria reauthorization 12 months.
- Prescriber specialties required vary by indication (see prior authorization block).
Definitions and Condition Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.